1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis

Efficacy Comparable To Gilead/Galapagos JAK Inhibitor Filgotinib

 
• By Mandy Jackson

Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response. 

Medical Concept: Ulcerative Colitis on Black Chalkboard. Medical Concept: Ulcerative Colitis - Black Chalkboard with Hand Drawn Text and Red Stethoscope. Top View. 3D Rendering.
Zeposia could be the first S1P receptor modulator approved for UC • Source: Shutterstock

Bristol Myers Squibb Company is building a case for its S1P receptor modulator Zeposia (ozanimod) as an effective, safer oral option for the treatment of moderate to severe ulcerative colitis based on new results from the Phase III TRUE NORTH clinical trial and as a cornerstone product in the company’s growing immunology portfolio and potential multi-drug gastrointestinal franchise.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.